|  | Webcast
MDRNA, Inc. at ROTH OC Growth Stock Conference (Live)
03/15/10 at 4:30 p.m. PT |
At MDRNA we are focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics against human diseases including critical unmet medical needs in areas such as cancer, metabolic disorders and inflammation. More >>
|  | |
|
|
| Date | Title | | | 03/08/10 | MDRNA, Inc. Announces Upcoming Investor Conference Presentations| BOTHELL, WA, Mar 08, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that J. Michael French, MDRNA's
President and Chief Executive Officer, will provide an overview of
the Company and its progress in key programs at the following
upcoming conferences:
-- The ROTH 22nd Annual OC Growth Stock Conference, on Monday, March 15 at
4:30 p.m. Pacific Time at the Ritz-Carlton in Dana Point, California;
... |
|  | | 02/08/10 | MDRNA, Inc. Reports Positive Results for Its Proprietary siRNA
Delivery Technology| Data Demonstrates the Potential for Long-Term Stability of Drug ProductsBOTHELL, WA, Feb 08, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that its lead delivery system
formulation demonstrated exceptional stability over a one year period
under a variety of conditions. The DiLA2 formulation maintained in
vivo knockdown activity with no observed loss in potency over the
course of the year-long study w... |
| | | 02/08/10 | MDRNA, Inc. Receives Compliance Extension From NASDAQ| BOTHELL, WA, Feb 08, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced that it received a letter on
February 5, 2010 from The NASDAQ Stock Market, Inc. notifying the
Company that, as a result of Securities and Exchanges Commission
(SEC) approved changes to NASDAQ Listing Rules, MDRNA now has a grace
period of 180 days from its initial notice of non-compliance in which
to regain compliance with the $50 million minimum Market Value of
Listed Securities (MVLS) for continued... |
| | | 02/01/10 | MDRNA, Inc. to Present at the 12th Annual BIO CEO & Investor
Conference| Will Also Participate in a Panel Discussion on RNAi-Based TechnologyBOTHELL, WA, Feb 01, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that it will present at the 12th
Annual BIO CEO & Investor Conference being held at the Waldorf
Astoria Hotel in New York City, New York. J. Michael French, MDRNA's
President and Chief Executive Officer, will provide an overview of
the Company and its progress in k... |
| |
|
|
| Primary IR Contact | John Woolford
Westwicke Partners
Phone: 443-213-0506
E-mail: ir@mdrnainc.com |
| | | Transfer Agent | American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
Phone: 877-777-0800
Corporate Website: http://www.amstock.com
|
| | Legal | Pryor Cashman Sherman & Flynn LLP
410 Park Avenue
New York, NY 10022
Phone: (212) 421-4100
Corporate Website: http://www.pryorcashman.com
|
| | | Accountants | KPMG
3100 Two Union Square
801 Second Avenue
Seattle, WA 98104
Phone: 206-292-1500
Corporate Website: http://www.kpmgcampus.com
|
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
